rs116941264 - BDP1P - RNA5SP461
Magnitude 4.5 · 1 study on file
Reported associations
-
A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture. - Calcified tissue international (2020) · Kharazmi M, Michaëlsson K, Schilcher J, Eriksson N, Melhus H, Wadelius M, Hallberg P · PubMed 31006051
Atypical femoral fracture is a well-documented adverse reaction to bisphosphonates. It is strongly related to duration of bisphosphonate use, and the risk declines rapidly after drug withdrawal. The mechanism behind bisphosphonate-associated atypical femoral fracture is unclear, but a genetic predisposition has been suggested. With the aim to identify common genetic variants that could be used for preemptive genetic testing, we performed a genome-wide association study. Cases were recruited mainly through reports of adverse drug reactions sent to the Swedish Medical Products Agency on a nation-wide basis. We compared atypical femoral fracture cases (n = 51) with population-based controls (n = 4891), and to reduce the possibility of confounding by indication, we also compared with b
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
rs116941264-A allele and bisphosphonate therapy Moderate
The A allele of rs116941264 is associated with significantly increased risk of atypical femoral fracture in patients receiving bisphosphonate therapy for osteoporosis
If taking or considering bisphosphonate therapy, discuss this genetic risk with your prescribing physician